Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A, von Strandmann EP. Böll B, et al. Among authors: lundgren k. Clin Cancer Res. 2009 Aug 15;15(16):5108-16. doi: 10.1158/1078-0432.CCR-09-0213. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671844
Orally active purine-based inhibitors of the heat shock protein 90.
Biamonte MA, Shi J, Hong K, Hurst DC, Zhang L, Fan J, Busch DJ, Karjian PL, Maldonado AA, Sensintaffar JL, Yang YC, Kamal A, Lough RE, Lundgren K, Burrows FJ, Timony GA, Boehm MF, Kasibhatla SR. Biamonte MA, et al. Among authors: lundgren k. J Med Chem. 2006 Jan 26;49(2):817-28. doi: 10.1021/jm0503087. J Med Chem. 2006. PMID: 16420067
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR, Hong K, Biamonte MA, Busch DJ, Karjian PL, Sensintaffar JL, Kamal A, Lough RE, Brekken J, Lundgren K, Grecko R, Timony GA, Ran Y, Mansfield R, Fritz LC, Ulm E, Burrows FJ, Boehm MF. Kasibhatla SR, et al. Among authors: lundgren k. J Med Chem. 2007 Jun 14;50(12):2767-78. doi: 10.1021/jm050752+. Epub 2007 May 8. J Med Chem. 2007. PMID: 17488003
EC144 is a potent inhibitor of the heat shock protein 90.
Shi J, Van de Water R, Hong K, Lamer RB, Weichert KW, Sandoval CM, Kasibhatla SR, Boehm MF, Chao J, Lundgren K, Timple N, Lough R, Ibanez G, Boykin C, Burrows FJ, Kehry MR, Yun TJ, Harning EK, Ambrose C, Thompson J, Bixler SA, Dunah A, Snodgrass-Belt P, Arndt J, Enyedy IJ, Li P, Hong VS, McKenzie A, Biamonte MA. Shi J, et al. Among authors: lundgren k. J Med Chem. 2012 Sep 13;55(17):7786-95. doi: 10.1021/jm300810x. Epub 2012 Aug 31. J Med Chem. 2012. PMID: 22938030
7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
Zhang L, Fan J, Vu K, Hong K, Le Brazidec JY, Shi J, Biamonte M, Busch DJ, Lough RE, Grecko R, Ran Y, Sensintaffar JL, Kamal A, Lundgren K, Burrows FJ, Mansfield R, Timony GA, Ulm EH, Kasibhatla SR, Boehm MF. Zhang L, et al. Among authors: lundgren k. J Med Chem. 2006 Aug 24;49(17):5352-62. doi: 10.1021/jm051146h. J Med Chem. 2006. PMID: 16913725
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?
Barker CR, Hamlett J, Pennington SR, Burrows F, Lundgren K, Lough R, Watson AJ, Jenkins JR. Barker CR, et al. Among authors: lundgren k. Int J Cancer. 2006 Jun 1;118(11):2685-93. doi: 10.1002/ijc.21717. Int J Cancer. 2006. PMID: 16385570
253 results